Pharsight

Jardiance patents expiration

JARDIANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(3 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7713938

(Pediatric)

BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Oct, 2027

(4 years from now)

US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(5 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(6 years from now)

US8551957

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Apr, 2030

(6 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(10 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(11 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(11 years from now)

US9949997

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Nov, 2034

(11 years from now)

US9949998

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Dec, 2034

(11 years from now)

Jardiance is owned by Boehringer Ingelheim.

Jardiance contains Empagliflozin.

Jardiance has a total of 14 drug patents out of which 0 drug patents have expired.

Jardiance was authorised for market use on 01 August, 2014.

Jardiance is available in tablet;oral dosage forms.

Jardiance can be used as method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin, method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin; method for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus and heart failure by once daily administration of empagliflozin; method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin, method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin.

The generics of Jardiance are possible to be released after 11 December, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jun 20, 2026
New Indication (I) Aug 18, 2024
M (M) Feb 24, 2025
Pediatric Exclusivity (PED) Aug 24, 2025

Drugs and Companies using EMPAGLIFLOZIN ingredient

Market Authorisation Date: 01 August, 2014

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1....

Dosage: TABLET;ORAL

How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage

JARDIANCE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic